Skip to main content

Table 5 Quality of life (SF36 v2) at inclusion regarding IgRT modalities

From: Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”

  Hospital-based IVIg N = 46 Home-based IVIg N = 13 Home-based SCIg N = 57 p
Physical functioning 47.61 ± 9.78 48.79 ± 12.74 49.11 ± 9.97 0.76
Role physical 44.66 ± 10.04 48.54 ± 8.91 45.24 ± 11.39 0.56
Bodily pain 47.13 ± 10.63 49.63 ± 11.62 46.75 ± 13.81 0.78
General health 37.39 ± 10.35 34.34 ± 10.04 37.70 ± 10.38 0.61
Vitality 44.11 ± 11.03 48.69 ± 10.02 45.38 ± 10.19 0.43
Social functioning 43.15 ± 11.25 40.98 ± 11.03 43.52 ± 13.51 0.83
Role emotional 41.28 ± 14.29 40.33 ± 11.53 44.29 ± 13.89 0.47
Mental health 42.19 ± 12.56 42.07 ± 13.78 40.58 ± 12.36 0.81
Physical component score 46.25 ± 9.39 49.41 ± 9.04 46.94 ± 10.48 0.64
Mental component score 40.93 ± 13.70 39.51 ± 13.01 41.42 ± 12.98 0.91
  1. Mixed model with route and place and interaction of route by place for administration as fixed factors and study center as random factor
\